Jonathan Douxfils
Overview
Explore the profile of Jonathan Douxfils including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
184
Citations
2265
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Beaudart C, Veronese N, Douxfils J, Amuthavalli Thiyagarajan J, Bolzetta F, Albanese P, et al.
Osteoporos Int
. 2025 Mar;
PMID: 40047881
Osteoporosis, defined by reduced bone mineral density and macro- and micro-architectural degradation, leads to increased fracture risk, particularly in aging populations. While randomized controlled trials (RCTs) demonstrate that PTH1 receptor...
2.
Creinin M, Foidart J, Gemzell-Danielsson K, Flerin N, Kubba A, Gaspard U, et al.
Contraception
. 2025 Mar;
:110861.
PMID: 40024362
Objectives: To evaluate cardiovascular safety outcomes in estetrol 15mg/drospirenone 3mg users with cardiovascular risk factors. Study Design: We performed a secondary analysis of two open-label contraceptive phase-3 trials that enrolled...
3.
Didembourg M, David C, Morimont L, Cransquint E, Favresse J, Douxfils J, et al.
Heliyon
. 2025 Jan;
11(1):e41249.
PMID: 39811280
Background: SARS-CoV-2 infection during pregnancy poses health risks to both mother and fetus. This study investigates neutralizing antibodies (NAbs) against the SARS-CoV-2 JN.1 Omicron subvariant in pregnant women, focusing on...
4.
Lamoine S, Jury V, Fourneyron V, Douxfils J, Teissandier D, Talon L, et al.
Res Pract Thromb Haemost
. 2024 Nov;
8(7):102576.
PMID: 39498238
Background: The incidence of cardiovascular diseases is increasing in persons with hemophilia A (HA). Therefore, anticoagulant therapy based on direct oral anticoagulants (DOACs) may be needed, despite the bleeding risk....
5.
Creinin M, Douxfils J, Beaudart C, Foidart J
Eur J Obstet Gynecol Reprod Biol
. 2024 Nov;
303:362-363.
PMID: 39496532
No abstract available.
6.
Didembourg M, Locquet M, Raskin L, Tchimchoua B, Dogne J, Beaudart C, et al.
Contraception
. 2024 Oct;
142():110727.
PMID: 39424122
Objectives: Pharmacovigilance data analysis can accelerate the identification of drug-related safety signals or reassure on the safety profile. This study evaluates the venous thromboembolism (VTE) risk of newer combined oral...
7.
Kobayashi T, Hirayama M, Nogami M, Meguro K, Iiduka M, Foidart J, et al.
Clin Appl Thromb Hemost
. 2024 Sep;
30:10760296241286514.
PMID: 39327996
Venous thromboembolism is a serious safety concern in women using combined oral contraceptives; ethinyl estradiol (EE) is widely used as an estrogen. Estetrol (E4) is a native estrogen with selective...
8.
Douxfils J, Beaudart C, Dogne J
Expert Opin Pharmacother
. 2024 Sep;
25(14):1971-1972.
PMID: 39323314
No abstract available.
9.
Van Dievoet M, Boudjeltia K, Rousseaux M, Douxfils J, Lisman T, Stephenne X
Res Pract Thromb Haemost
. 2024 Sep;
8(6):102551.
PMID: 39290990
No abstract available.
10.
Favresse J, Tre-Hardy M, Gillot C, Cupaiolo R, Wilmet A, Beukinga I, et al.
Heliyon
. 2024 Sep;
10(16):e36116.
PMID: 39247272
Introduction: Some studies suggest that the monovalent mRNA-1273 vaccine is more effective than BNT162b2 in producing higher levels of antibodies. However, limited data are available, and the methods used are...